Cagrisema vs Wegovy: How Does the New Combination Stack Up?

What exactly is cagrisema, and where is it in development?

Cagrisema pairs semaglutide (the same GLP-1 receptor agonist found in Wegovy) with cagrilintide, a long-acting analogue of the hormone amylin. Amylin is released from the pancreas alongside insulin and plays its own role in appetite suppression and slowing how fast the stomach empties. The thinking behind combining the two pathways is that they may act on different parts of the appetite-regulation system and, together, produce greater weight reduction than either agent alone.

Phase 2 data suggested that the combination could achieve around 15–22% average body-weight reduction over roughly 32 weeks, which prompted Novo Nordisk to advance it into the REDEFINE phase 3 programme. Results from those larger trials began reporting in 2025. Even so, a completed phase 3 trial is only the first step: a regulatory submission to the MHRA, a review process, a licensing decision and then a supply chain build-out must all follow before the medicine could be prescribed in the UK. That timeline typically spans several years from a positive trial read-out. There is no cagrisema product on the UK market, and no date has been announced for a UK submission.

For anyone trying to compare it with Wegovy today, the honest position is that the two are at very different stages. You can explore how Wegovy compares with other licensed options on the Wegovy comparison overview.

How do the efficacy numbers compare, and what are their limits?

Wegovy's track record comes from the STEP programme, large, well-powered, peer-reviewed trials that formed the basis of its MHRA licence and NICE appraisal (TA875). The STEP 1 trial, published in the New England Journal of Medicine, reported roughly 15% average body-weight reduction over 68 weeks at the 2.4 mg maintenance dose. The more recently approved 7.2 mg single-dose pen showed around 20.7% average loss over 72 weeks in its trial, narrowing the gap with tirzepatide considerably.

Cagrisema's phase 3 REDEFINE numbers are more varied by trial arm and duration, and direct comparisons with Wegovy's STEP data are imprecise because the trials used different populations, endpoints and timeframes. That matters. Cross-trial comparisons can be misleading: a drug that performs better in a shorter trial with a selected population may not outperform a competitor in a head-to-head study. Until a randomised head-to-head trial pitting cagrisema against semaglutide 2.4 mg is completed and published, any claim that one is definitively superior should be read with scepticism. The semaglutide and Wegovy explainer covers how semaglutide's evidence base was built and what the licence actually covers.

The table below sets out the factual comparison as it stands today.

Is cagrisema likely to be more effective, and does that mean waiting makes sense?

The phase 3 data for cagrisema are genuinely interesting, and there is a plausible biological case for the dual mechanism producing larger weight reductions on average. But licensing, manufacturing at scale and NHS or private-market access are separate questions from trial efficacy, and each takes time. A medicine that reads out positively from trials in 2025 is unlikely to be prescribable in the UK before 2027 at the earliest, and NHS availability would follow its own appraisal process after that.

There is also the question of what waiting costs. Weight-related health conditions (raised blood pressure, dyslipidaemia, obstructive sleep apnoea) are not on pause. For many people, two years on a licensed, clinically supervised treatment produces meaningful health benefits that are real and measurable now. The full Wegovy guide sets out what the treatment involves, who it suits and how the dose escalation works in practice.

That said, nobody should feel pressured. If your situation is complex or you want to understand all the licensed alternatives side by side, the GLP-1 treatment comparison is a useful starting point, and a prescriber can talk through what timing makes clinical sense for you specifically.

What should you do if Wegovy is the available option you are considering?

Wegovy is a prescription-only medicine. The only legal route to it in the UK is through a clinical assessment carried out by a qualified prescriber, who reviews your health history, weight, medicines and any relevant conditions before deciding whether to prescribe. At nume, that assessment is carried out by a GPhC-registered Independent Prescriber, you can verify our pharmacy on the GPhC register (premises number 9012878). There is no algorithm making that decision.

The licensed eligibility criteria for Wegovy on a private basis are adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure, raised cholesterol or type 2 diabetes. BMI alone is never the whole picture, the prescriber takes the full clinical view. Lower thresholds apply for some ethnic backgrounds under UK guidance. Our free consultation page explains exactly what the assessment involves and what happens after.

If you want to see how Wegovy sits alongside other options that are licensed and available now, the weight-loss treatment overview covers the full picture. For questions about Wegovy's relationship to Ozempic, the Wegovy vs Ozempic comparison is worth reading before you decide. And if cost is part of your thinking, the Wegovy cost guide sets out what private treatment actually includes and why the headline price is not always the full story.

Which medicine suits you is a clinical decision our prescribers make with you, based on your health, your history and what is actually available. Check your eligibility and start that conversation.